# DocuSign timeline entity: /record/docusign.md id: ent_docusign ## undated - undated | fiscal_year_end | 01-31 | valid | [clm_01193D94442B](/claim/clm_01193D94442B.md) - undated | ticker | DOCU | valid | [clm_3BDAA12F7648](/claim/clm_3BDAA12F7648.md) - undated | cik | 0001261333 | valid | [clm_85E12C77DFE7](/claim/clm_85E12C77DFE7.md) - undated | headquarters | San Francisco | valid | [clm_BAC0DE4F8F89](/claim/clm_BAC0DE4F8F89.md) - undated | sic_industry | Services-Prepackaged Software (7372) | valid | [clm_D15F6099A6EC](/claim/clm_D15F6099A6EC.md) - undated | listed_on | Nasdaq | valid | [clm_D5BEB65B7AD3](/claim/clm_D5BEB65B7AD3.md) - undated | state_of_incorporation | DE | valid | [clm_E0245696A86C](/claim/clm_E0245696A86C.md) - undated | legal_form | Delaware corporation | unverified | [clm_12745AB6359A](/claim/clm_12745AB6359A.md) - undated | industry | business software industry | valid | [clm_4F5D378F6226](/claim/clm_4F5D378F6226.md) - undated | website | http://www.docusign.com/ | unverified | [clm_7971297CD965](/claim/clm_7971297CD965.md) - undated | country | United States | valid | [clm_81889EF92AC9](/claim/clm_81889EF92AC9.md) - undated | member_of | CA/Browser Forum | valid | [clm_DF9689FA0934](/claim/clm_DF9689FA0934.md) - undated | member_of | Business Software Alliance | valid | [clm_EB7F83EAC97C](/claim/clm_EB7F83EAC97C.md) ## 2003 - 2003-08-25 | registrant_name | DOCUSIGN, INC. | valid | [clm_6572FE61EEE1](/claim/clm_6572FE61EEE1.md) ## 2009 - 2009-01-12 | x_username | DocuSign | unverified | [clm_6E3105EF9EB0](/claim/clm_6E3105EF9EB0.md) ## 2011 - 2011-01-20 | x_username | DocuSignAPI | unverified | [clm_084F1A768EC8](/claim/clm_084F1A768EC8.md) ## 2016 - 2016-01-31 to 2017-01-31 | total_equity | -276,145,000 United States dollar | superseded | [clm_35990D596644](/claim/clm_35990D596644.md) ## 2017 - 2017-01-31 to 2018-01-31 | total_equity | -347,355,000 United States dollar | superseded | [clm_06046AD57194](/claim/clm_06046AD57194.md) - 2017-01-31 to 2018-01-31 | operating_income | -115,817,000 United States dollar | superseded | [clm_071D065E1688](/claim/clm_071D065E1688.md) - 2017-01-31 to 2018-01-31 | revenue | 381,459,000 United States dollar | superseded | [clm_20AA8FDE7D12](/claim/clm_20AA8FDE7D12.md) - 2017-01-31 to 2018-01-31 | net_income | -115,412,000 United States dollar | superseded | [clm_3D615F719A52](/claim/clm_3D615F719A52.md) - 2017-01-31 to 2018-01-31 | research_and_development | 89,652,000 United States dollar | superseded | [clm_595BC7DDC4FB](/claim/clm_595BC7DDC4FB.md) - 2017-04-30 to 2017-07-31 | quarterly_net_income | -19,382,000 United States dollar | superseded | [clm_9455DE34A918](/claim/clm_9455DE34A918.md) - 2017-04-30 to 2017-07-31 | quarterly_operating_income | -19,264,000 United States dollar | superseded | [clm_BB1C23347260](/claim/clm_BB1C23347260.md) - 2017-04-30 to 2017-07-31 | quarterly_revenue | 113,498,000 United States dollar | superseded | [clm_D272F0306D9D](/claim/clm_D272F0306D9D.md) - 2017-04-30 to 2017-07-31 | quarterly_research_and_development | 22,708,000 United States dollar | superseded | [clm_D3550177A745](/claim/clm_D3550177A745.md) - 2017-07-31 to 2017-10-31 | quarterly_net_income | -12,037,000 United States dollar | superseded | [clm_01C976DFA56E](/claim/clm_01C976DFA56E.md) - 2017-07-31 to 2017-10-31 | quarterly_operating_income | -13,781,000 United States dollar | superseded | [clm_0F22BE5A2A78](/claim/clm_0F22BE5A2A78.md) - 2017-07-31 to 2017-10-31 | quarterly_revenue | 125,543,000 United States dollar | superseded | [clm_65E68081787A](/claim/clm_65E68081787A.md) - 2017-07-31 to 2017-10-31 | quarterly_research_and_development | 23,767,000 United States dollar | superseded | [clm_902AEE54F22A](/claim/clm_902AEE54F22A.md) - 2017-10-31 to 2018-04-30 | quarterly_revenue | 130,589,000 United States dollar | superseded | [clm_2F9920BEF54A](/claim/clm_2F9920BEF54A.md) - 2017-10-31 to 2018-04-30 | quarterly_net_income | -14,505,000 United States dollar | superseded | [clm_696F6A3D9806](/claim/clm_696F6A3D9806.md) - 2017-10-31 to 2018-04-30 | quarterly_operating_income | -12,343,000 United States dollar | superseded | [clm_B79C2ED312A7](/claim/clm_B79C2ED312A7.md) - 2017-10-31 to 2018-04-30 | quarterly_research_and_development | 22,522,000 United States dollar | superseded | [clm_F15B7AC0D86E](/claim/clm_F15B7AC0D86E.md) ## 2018 - 2018-01-31 to 2018-04-30 | total_assets | 619,973,000 United States dollar | superseded | [clm_1A9F31A6BE84](/claim/clm_1A9F31A6BE84.md) - 2018-01-31 to 2018-04-30 | total_equity | -338,648,000 United States dollar | superseded | [clm_49BA80104E24](/claim/clm_49BA80104E24.md) - 2018-01-31 to 2018-04-30 | cash_and_equivalents | 256,867,000 United States dollar | superseded | [clm_4B8BA206D720](/claim/clm_4B8BA206D720.md) - 2018-01-31 to 2019-01-31 | research_and_development | 92,428,000 United States dollar | superseded | [clm_698E66BDDD23](/claim/clm_698E66BDDD23.md) - 2018-01-31 to 2019-01-31 | operating_income | -51,653,000 United States dollar | superseded | [clm_762F2E74EAC7](/claim/clm_762F2E74EAC7.md) - 2018-01-31 to 2019-01-31 | net_income | -52,276,000 United States dollar | superseded | [clm_B8EEA1757F01](/claim/clm_B8EEA1757F01.md) - 2018-01-31 to 2019-01-31 | revenue | 518,504,000 United States dollar | superseded | [clm_B9192D9A032C](/claim/clm_B9192D9A032C.md) - 2018-04-30 to 2018-07-31 | quarterly_revenue | 155,808,000 United States dollar | superseded | [clm_24CC266C32DF](/claim/clm_24CC266C32DF.md) - 2018-04-30 to 2018-07-31 | total_equity | -333,728,000 United States dollar | superseded | [clm_5E91F0F16275](/claim/clm_5E91F0F16275.md) - 2018-04-30 to 2018-07-31 | quarterly_net_income | -270,687,000 United States dollar | superseded | [clm_669C061C4D2F](/claim/clm_669C061C4D2F.md) - 2018-04-30 to 2018-07-31 | cash_and_equivalents | 269,429,000 United States dollar | superseded | [clm_9B1FA459F34C](/claim/clm_9B1FA459F34C.md) - 2018-04-30 to 2018-07-31 | total_assets | 614,472,000 United States dollar | superseded | [clm_A082558EF0B4](/claim/clm_A082558EF0B4.md) - 2018-04-30 to 2018-07-31 | quarterly_operating_income | -267,558,000 United States dollar | superseded | [clm_C2A0C3454836](/claim/clm_C2A0C3454836.md) - 2018-04-30 to 2018-07-31 | quarterly_research_and_development | 70,870,000 United States dollar | superseded | [clm_CE0C937CC8FD](/claim/clm_CE0C937CC8FD.md) - 2018-05-31 to 2018-08-31 | shares_outstanding | 156,585,256 shares | superseded | [clm_AB3E93933202](/claim/clm_AB3E93933202.md) - 2018-07-31 to 2018-10-31 | quarterly_revenue | 167,044,000 United States dollar | superseded | [clm_30D56234EB2F](/claim/clm_30D56234EB2F.md) - 2018-07-31 to 2018-10-31 | quarterly_research_and_development | 33,773,000 United States dollar | superseded | [clm_41644ED867A1](/claim/clm_41644ED867A1.md) - 2018-07-31 to 2018-10-31 | total_assets | 1,169,698,000 United States dollar | superseded | [clm_670DB6310DEA](/claim/clm_670DB6310DEA.md) - 2018-07-31 to 2018-10-31 | total_equity | 743,470,000 United States dollar | superseded | [clm_B940CD3A4076](/claim/clm_B940CD3A4076.md) - 2018-07-31 to 2018-10-31 | cash_and_equivalents | 818,795,000 United States dollar | superseded | [clm_C039E0D2D8E8](/claim/clm_C039E0D2D8E8.md) - 2018-07-31 to 2018-10-31 | quarterly_operating_income | -37,720,000 United States dollar | superseded | [clm_CEEFCB766C39](/claim/clm_CEEFCB766C39.md) - 2018-07-31 to 2018-10-31 | quarterly_net_income | -36,714,000 United States dollar | superseded | [clm_F82E6BC5F678](/claim/clm_F82E6BC5F678.md) - 2018-08-31 to 2018-11-30 | shares_outstanding | 156,808,589 shares | superseded | [clm_6C2D55C65757](/claim/clm_6C2D55C65757.md) - 2018-10-31 to 2019-04-30 | quarterly_revenue | 178,385,000 United States dollar | superseded | [clm_4878EF28AECE](/claim/clm_4878EF28AECE.md) - 2018-10-31 to 2019-01-31 | total_equity | 810,169,000 United States dollar | superseded | [clm_5B04A7CDDFFA](/claim/clm_5B04A7CDDFFA.md) - 2018-10-31 to 2019-04-30 | quarterly_net_income | -52,813,000 United States dollar | superseded | [clm_84295EF3B18F](/claim/clm_84295EF3B18F.md) - 2018-10-31 to 2019-01-31 | cash_and_equivalents | 1,094,133,000 United States dollar | superseded | [clm_8B4F03AC0B81](/claim/clm_8B4F03AC0B81.md) - 2018-10-31 to 2019-04-30 | quarterly_operating_income | -58,417,000 United States dollar | superseded | [clm_D8639E2CBC85](/claim/clm_D8639E2CBC85.md) - 2018-10-31 to 2019-04-30 | quarterly_research_and_development | 38,404,000 United States dollar | superseded | [clm_E3FC0E80CD03](/claim/clm_E3FC0E80CD03.md) - 2018-10-31 to 2019-01-31 | total_assets | 1,719,436,000 United States dollar | superseded | [clm_E56C87D76B24](/claim/clm_E56C87D76B24.md) - 2018-11-30 to 2019-02-28 | shares_outstanding | 165,250,665 shares | superseded | [clm_0C52C67BFF2E](/claim/clm_0C52C67BFF2E.md) ## 2019 - 2019-01-31 to 2020-01-31 | net_income | -426,458,000 United States dollar | superseded | [clm_2736C5C15094](/claim/clm_2736C5C15094.md) - 2019-01-31 to 2020-01-31 | revenue | 700,969,000 United States dollar | superseded | [clm_447BA71AF2D6](/claim/clm_447BA71AF2D6.md) - 2019-01-31 to 2019-04-30 | total_equity | 614,362,000 United States dollar | superseded | [clm_4D783834F1C2](/claim/clm_4D783834F1C2.md) - 2019-01-31 to 2019-04-30 | cash_and_equivalents | 517,811,000 United States dollar | superseded | [clm_4DFA25FBE0EA](/claim/clm_4DFA25FBE0EA.md) - 2019-01-31 to 2020-01-31 | research_and_development | 185,968,000 United States dollar | superseded | [clm_881235EE6A76](/claim/clm_881235EE6A76.md) - 2019-01-31 to 2020-01-31 | operating_income | -426,323,000 United States dollar | superseded | [clm_D4503FEA0E28](/claim/clm_D4503FEA0E28.md) - 2019-01-31 to 2019-04-30 | total_assets | 1,615,417,000 United States dollar | superseded | [clm_FB5C5E1E0FA1](/claim/clm_FB5C5E1E0FA1.md) - 2019-02-28 to 2019-05-31 | shares_outstanding | 169,900,000 shares | superseded | [clm_0F54BBB9EFF0](/claim/clm_0F54BBB9EFF0.md) - 2019-04-30 to 2019-07-31 | quarterly_revenue | 213,962,000 United States dollar | superseded | [clm_1D5AA3B32A70](/claim/clm_1D5AA3B32A70.md) - 2019-04-30 to 2019-07-31 | quarterly_operating_income | -42,437,000 United States dollar | superseded | [clm_2B7E2DA4875E](/claim/clm_2B7E2DA4875E.md) - 2019-04-30 to 2019-07-31 | quarterly_research_and_development | 37,183,000 United States dollar | superseded | [clm_360C44E8758F](/claim/clm_360C44E8758F.md) - 2019-04-30 to 2019-07-31 | quarterly_net_income | -45,722,000 United States dollar | superseded | [clm_4F3B636156B5](/claim/clm_4F3B636156B5.md) - 2019-04-30 to 2019-07-31 | total_assets | 1,738,400,000 United States dollar | superseded | [clm_56AB0741E0CE](/claim/clm_56AB0741E0CE.md) - 2019-04-30 to 2019-07-31 | total_equity | 597,682,000 United States dollar | superseded | [clm_758B9D8C014D](/claim/clm_758B9D8C014D.md) - 2019-04-30 to 2019-07-31 | cash_and_equivalents | 236,476,000 United States dollar | superseded | [clm_D056458316C2](/claim/clm_D056458316C2.md) - 2019-05-31 to 2019-08-31 | shares_outstanding | 173,800,000 shares | superseded | [clm_568BE117045C](/claim/clm_568BE117045C.md) - 2019-07-31 to 2019-10-31 | quarterly_research_and_development | 47,517,000 United States dollar | superseded | [clm_4784291DA551](/claim/clm_4784291DA551.md) - 2019-07-31 to 2019-10-31 | cash_and_equivalents | 224,290,000 United States dollar | superseded | [clm_50927BC04F94](/claim/clm_50927BC04F94.md) - 2019-07-31 to 2019-10-31 | total_equity | 566,679,000 United States dollar | superseded | [clm_7E7A968D5F2B](/claim/clm_7E7A968D5F2B.md) - 2019-07-31 to 2019-10-31 | quarterly_revenue | 235,612,000 United States dollar | superseded | [clm_83A0F26743B6](/claim/clm_83A0F26743B6.md) - 2019-07-31 to 2019-10-31 | quarterly_net_income | -68,632,000 United States dollar | superseded | [clm_8F9F9FA643F2](/claim/clm_8F9F9FA643F2.md) - 2019-07-31 to 2019-10-31 | total_assets | 1,761,836,000 United States dollar | superseded | [clm_A390099B8EC1](/claim/clm_A390099B8EC1.md) - 2019-07-31 to 2019-10-31 | quarterly_operating_income | -64,722,000 United States dollar | superseded | [clm_C17C4DB7A0BA](/claim/clm_C17C4DB7A0BA.md) - 2019-08-31 to 2019-11-30 | shares_outstanding | 176,000,000 shares | superseded | [clm_C3A10B1BAD26](/claim/clm_C3A10B1BAD26.md) - 2019-10-31 to 2020-01-31 | cash_and_equivalents | 197,697,000 United States dollar | superseded | [clm_1AC574E87E56](/claim/clm_1AC574E87E56.md) - 2019-10-31 to 2020-04-30 | quarterly_research_and_development | 48,758,000 United States dollar | superseded | [clm_3F4B9BFD96AA](/claim/clm_3F4B9BFD96AA.md) - 2019-10-31 to 2020-04-30 | quarterly_net_income | -46,598,000 United States dollar | superseded | [clm_4367717E4AB6](/claim/clm_4367717E4AB6.md) - 2019-10-31 to 2020-01-31 | total_assets | 1,786,365,000 United States dollar | superseded | [clm_68AD43834DB9](/claim/clm_68AD43834DB9.md) - 2019-10-31 to 2020-01-31 | total_equity | 569,362,000 United States dollar | superseded | [clm_6C3752636017](/claim/clm_6C3752636017.md) - 2019-10-31 to 2020-04-30 | quarterly_operating_income | -43,997,000 United States dollar | superseded | [clm_701F588A97D6](/claim/clm_701F588A97D6.md) - 2019-10-31 to 2020-04-30 | quarterly_revenue | 249,502,000 United States dollar | superseded | [clm_BB2943ECF9B9](/claim/clm_BB2943ECF9B9.md) - 2019-11-30 to 2020-02-28 | shares_outstanding | 179,455,116 shares | superseded | [clm_382078DB3191](/claim/clm_382078DB3191.md) ## 2020 - 2020-01-01 | subsidiary | Liveoak Technologies | valid | [clm_81178F145061](/claim/clm_81178F145061.md) - 2020-01-31 to 2021-01-31 | net_income | -208,359,000 United States dollar | superseded | [clm_111895AB5A6D](/claim/clm_111895AB5A6D.md) - 2020-01-31 to 2021-01-31 | research_and_development | 185,552,000 United States dollar | superseded | [clm_53B3D6A9F3F1](/claim/clm_53B3D6A9F3F1.md) - 2020-01-31 to 2021-01-31 | operating_income | -193,509,000 United States dollar | superseded | [clm_5C0C29B0AAD1](/claim/clm_5C0C29B0AAD1.md) - 2020-01-31 to 2021-01-31 | revenue | 973,971,000 United States dollar | superseded | [clm_7F20F1721E1D](/claim/clm_7F20F1721E1D.md) - 2020-01-31 to 2020-04-30 | total_equity | 546,327,000 United States dollar | superseded | [clm_83501B91196E](/claim/clm_83501B91196E.md) - 2020-01-31 to 2020-04-30 | cash_and_equivalents | 241,203,000 United States dollar | superseded | [clm_8749B2C4CDC4](/claim/clm_8749B2C4CDC4.md) - 2020-01-31 to 2020-04-30 | total_assets | 1,891,138,000 United States dollar | superseded | [clm_980FBB96942A](/claim/clm_980FBB96942A.md) - 2020-02-28 to 2020-05-29 | shares_outstanding | 181,456,115 shares | superseded | [clm_F336A832C110](/claim/clm_F336A832C110.md) - 2020-04-30 to 2020-07-31 | total_assets | 1,921,488,000 United States dollar | superseded | [clm_0F986FAB9397](/claim/clm_0F986FAB9397.md) - 2020-04-30 to 2020-07-31 | quarterly_operating_income | -41,853,000 United States dollar | superseded | [clm_3A00024832D3](/claim/clm_3A00024832D3.md) - 2020-04-30 to 2020-07-31 | cash_and_equivalents | 442,237,000 United States dollar | superseded | [clm_4AD6BE79B144](/claim/clm_4AD6BE79B144.md) - 2020-04-30 to 2020-07-31 | quarterly_revenue | 297,017,000 United States dollar | superseded | [clm_5498EE7F1E53](/claim/clm_5498EE7F1E53.md) - 2020-04-30 to 2020-07-31 | quarterly_net_income | -47,804,000 United States dollar | superseded | [clm_697663384AC1](/claim/clm_697663384AC1.md) - 2020-04-30 to 2020-07-31 | total_equity | 522,788,000 United States dollar | superseded | [clm_78AB9B040304](/claim/clm_78AB9B040304.md) - 2020-04-30 to 2020-07-31 | quarterly_research_and_development | 54,234,000 United States dollar | superseded | [clm_F992FD5F29EF](/claim/clm_F992FD5F29EF.md) - 2020-05-29 to 2020-08-31 | shares_outstanding | 183,508,855 shares | superseded | [clm_7D2128D2A7EA](/claim/clm_7D2128D2A7EA.md) - 2020-07-31 to 2020-10-31 | quarterly_net_income | -64,560,000 United States dollar | superseded | [clm_02DBCE9F48B1](/claim/clm_02DBCE9F48B1.md) - 2020-07-31 to 2020-10-31 | total_equity | 501,891,000 United States dollar | superseded | [clm_40110C8BC3F0](/claim/clm_40110C8BC3F0.md) - 2020-07-31 to 2020-10-31 | quarterly_operating_income | -58,635,000 United States dollar | superseded | [clm_6A4AF67BB983](/claim/clm_6A4AF67BB983.md) - 2020-07-31 to 2020-10-31 | quarterly_revenue | 342,209,000 United States dollar | superseded | [clm_7374B106E804](/claim/clm_7374B106E804.md) - 2020-07-31 to 2020-10-31 | quarterly_research_and_development | 63,791,000 United States dollar | superseded | [clm_757B7D1E4675](/claim/clm_757B7D1E4675.md) - 2020-07-31 to 2020-10-31 | total_assets | 2,053,310,000 United States dollar | superseded | [clm_C73AEED92E87](/claim/clm_C73AEED92E87.md) - 2020-07-31 to 2020-10-31 | cash_and_equivalents | 404,262,000 United States dollar | superseded | [clm_D7DCB85ACC21](/claim/clm_D7DCB85ACC21.md) - 2020-08-31 to 2020-11-30 | shares_outstanding | 185,164,889 shares | superseded | [clm_E31FA3FD9084](/claim/clm_E31FA3FD9084.md) - 2020-10-31 to 2021-04-30 | quarterly_operating_income | -48,470,000 United States dollar | superseded | [clm_0364DAD0A508](/claim/clm_0364DAD0A508.md) - 2020-10-31 to 2021-04-30 | quarterly_research_and_development | 73,362,000 United States dollar | superseded | [clm_19871BFF3C41](/claim/clm_19871BFF3C41.md) - 2020-10-31 to 2021-04-30 | quarterly_revenue | 382,923,000 United States dollar | superseded | [clm_210A218A30ED](/claim/clm_210A218A30ED.md) - 2020-10-31 to 2021-01-31 | total_equity | 426,032,000 United States dollar | superseded | [clm_4258AAB00A2B](/claim/clm_4258AAB00A2B.md) - 2020-10-31 to 2021-04-30 | quarterly_net_income | -58,491,000 United States dollar | superseded | [clm_4F45542995A0](/claim/clm_4F45542995A0.md) - 2020-10-31 to 2021-01-31 | total_assets | 2,051,119,000 United States dollar | superseded | [clm_76860B2E179F](/claim/clm_76860B2E179F.md) - 2020-10-31 to 2021-01-31 | cash_and_equivalents | 374,984,000 United States dollar | superseded | [clm_FBCCB53DF803](/claim/clm_FBCCB53DF803.md) - 2020-11-30 to 2021-02-26 | shares_outstanding | 186,556,918 shares | superseded | [clm_AB8DF3B57163](/claim/clm_AB8DF3B57163.md) ## 2021 - 2021-01-31 to 2022-01-31 | revenue | 1,453,047,000 United States dollar | superseded | [clm_9382458672C2](/claim/clm_9382458672C2.md) - 2021-01-31 to 2022-01-31 | net_income | -243,267,000 United States dollar | superseded | [clm_9E5D99E88AA3](/claim/clm_9E5D99E88AA3.md) - 2021-01-31 to 2022-01-31 | research_and_development | 271,522,000 United States dollar | superseded | [clm_B99B759C658D](/claim/clm_B99B759C658D.md) - 2021-01-31 to 2021-04-30 | total_equity | 325,737,000 United States dollar | superseded | [clm_C37CC3F107CA](/claim/clm_C37CC3F107CA.md) - 2021-01-31 to 2022-01-31 | operating_income | -173,855,000 United States dollar | superseded | [clm_CBD0B2C8AC31](/claim/clm_CBD0B2C8AC31.md) - 2021-01-31 to 2021-04-30 | cash_and_equivalents | 566,055,000 United States dollar | superseded | [clm_DA6E292E497F](/claim/clm_DA6E292E497F.md) - 2021-01-31 to 2021-04-30 | total_assets | 2,336,507,000 United States dollar | superseded | [clm_FB2CC1F191A3](/claim/clm_FB2CC1F191A3.md) - 2021-02-26 to 2021-05-28 | shares_outstanding | 193,087,560 shares | superseded | [clm_3508319399A9](/claim/clm_3508319399A9.md) - 2021-04-30 to 2021-07-31 | quarterly_net_income | -8,354,000 United States dollar | superseded | [clm_1AAEFD8694B1](/claim/clm_1AAEFD8694B1.md) - 2021-04-30 to 2021-07-31 | quarterly_research_and_development | 85,416,000 United States dollar | superseded | [clm_247DF047C275](/claim/clm_247DF047C275.md) - 2021-04-30 to 2021-07-31 | total_equity | 243,237,000 United States dollar | superseded | [clm_43EFEF1F9D00](/claim/clm_43EFEF1F9D00.md) - 2021-04-30 to 2021-07-31 | cash_and_equivalents | 518,972,000 United States dollar | superseded | [clm_4C2D1632EA78](/claim/clm_4C2D1632EA78.md) - 2021-04-30 to 2021-07-31 | quarterly_revenue | 469,078,000 United States dollar | superseded | [clm_4C80E506DD4D](/claim/clm_4C80E506DD4D.md) - 2021-04-30 to 2021-07-31 | total_assets | 2,297,120,000 United States dollar | superseded | [clm_95A5BFDD3DC7](/claim/clm_95A5BFDD3DC7.md) - 2021-04-30 to 2021-07-31 | quarterly_operating_income | -10,737,000 United States dollar | superseded | [clm_BF6EF86D3B2E](/claim/clm_BF6EF86D3B2E.md) - 2021-05-28 to 2021-08-31 | shares_outstanding | 194,835,125 shares | superseded | [clm_9CB2FAACA890](/claim/clm_9CB2FAACA890.md) - 2021-07-31 to 2021-10-31 | quarterly_revenue | 511,844,000 United States dollar | superseded | [clm_2064BFB34FAA](/claim/clm_2064BFB34FAA.md) - 2021-07-31 to 2021-10-31 | total_assets | 2,355,687,000 United States dollar | superseded | [clm_6F7E965716FD](/claim/clm_6F7E965716FD.md) - 2021-07-31 to 2021-10-31 | total_equity | 211,876,000 United States dollar | superseded | [clm_835531568ADF](/claim/clm_835531568ADF.md) - 2021-07-31 to 2021-10-31 | quarterly_net_income | -25,501,000 United States dollar | superseded | [clm_9A528E17B775](/claim/clm_9A528E17B775.md) - 2021-07-31 to 2021-10-31 | quarterly_research_and_development | 94,651,000 United States dollar | superseded | [clm_AF783C6670A2](/claim/clm_AF783C6670A2.md) - 2021-07-31 to 2021-10-31 | cash_and_equivalents | 518,577,000 United States dollar | superseded | [clm_EF3662E6F144](/claim/clm_EF3662E6F144.md) - 2021-07-31 to 2021-10-31 | quarterly_operating_income | -22,611,000 United States dollar | superseded | [clm_F92E06F6BD3C](/claim/clm_F92E06F6BD3C.md) - 2021-08-31 to 2021-11-30 | shares_outstanding | 196,718,307 shares | superseded | [clm_A729D98961D4](/claim/clm_A729D98961D4.md) - 2021-10-31 to 2022-04-30 | quarterly_operating_income | -3,358,000 United States dollar | superseded | [clm_4997ADD9ACE1](/claim/clm_4997ADD9ACE1.md) - 2021-10-31 to 2022-01-31 | total_assets | 2,410,503,000 United States dollar | superseded | [clm_6BF07E354D74](/claim/clm_6BF07E354D74.md) - 2021-10-31 to 2022-01-31 | total_equity | 239,569,000 United States dollar | superseded | [clm_9850106431DF](/claim/clm_9850106431DF.md) - 2021-10-31 to 2022-04-30 | quarterly_research_and_development | 102,603,000 United States dollar | superseded | [clm_B721594C5388](/claim/clm_B721594C5388.md) - 2021-10-31 to 2022-01-31 | cash_and_equivalents | 503,884,000 United States dollar | superseded | [clm_BA9A2233DB0B](/claim/clm_BA9A2233DB0B.md) - 2021-10-31 to 2022-04-30 | quarterly_revenue | 545,463,000 United States dollar | superseded | [clm_E9F7BF7C2707](/claim/clm_E9F7BF7C2707.md) - 2021-10-31 to 2022-04-30 | quarterly_net_income | -5,676,000 United States dollar | superseded | [clm_FE7C2B9ADA49](/claim/clm_FE7C2B9ADA49.md) - 2021-11-30 to 2022-02-28 | shares_outstanding | 197,876,523 shares | superseded | [clm_35A02320E9B6](/claim/clm_35A02320E9B6.md) ## 2022 - 2022-01-31 to 2022-04-30 | total_assets | 2,541,265,000 United States dollar | superseded | [clm_02918052D199](/claim/clm_02918052D199.md) - 2022-01-31 to 2022-04-30 | total_equity | 275,503,000 United States dollar | superseded | [clm_48628927D631](/claim/clm_48628927D631.md) - 2022-01-31 to 2023-01-31 | net_income | -69,976,000 United States dollar | superseded | [clm_4DB0F0075FDD](/claim/clm_4DB0F0075FDD.md) - 2022-01-31 to 2023-01-31 | revenue | 2,107,213,000 United States dollar | superseded | [clm_4F508A911516](/claim/clm_4F508A911516.md) - 2022-01-31 to 2023-01-31 | operating_income | -61,884,000 United States dollar | superseded | [clm_58D358843ADC](/claim/clm_58D358843ADC.md) - 2022-01-31 to 2023-01-31 | research_and_development | 393,362,000 United States dollar | superseded | [clm_65CA748C757F](/claim/clm_65CA748C757F.md) - 2022-01-31 to 2022-04-30 | cash_and_equivalents | 509,059,000 United States dollar | superseded | [clm_EAD0B077F578](/claim/clm_EAD0B077F578.md) - 2022-02-28 to 2022-05-31 | shares_outstanding | 198,868,867 shares | superseded | [clm_73DD61C6966A](/claim/clm_73DD61C6966A.md) - 2022-04-30 to 2022-07-31 | total_equity | 348,949,000 United States dollar | superseded | [clm_2F3A96E542CD](/claim/clm_2F3A96E542CD.md) - 2022-04-30 to 2022-07-31 | quarterly_research_and_development | 112,227,000 United States dollar | superseded | [clm_700CB6E00C48](/claim/clm_700CB6E00C48.md) - 2022-04-30 to 2022-07-31 | quarterly_operating_income | -19,226,000 United States dollar | superseded | [clm_79B1052E9B56](/claim/clm_79B1052E9B56.md) - 2022-04-30 to 2022-07-31 | quarterly_net_income | -27,373,000 United States dollar | superseded | [clm_A81EBEB38F9A](/claim/clm_A81EBEB38F9A.md) - 2022-04-30 to 2022-07-31 | total_assets | 2,574,131,000 United States dollar | superseded | [clm_BB648154EC0B](/claim/clm_BB648154EC0B.md) - 2022-04-30 to 2022-07-31 | quarterly_revenue | 588,692,000 United States dollar | superseded | [clm_BCFA2D730A03](/claim/clm_BCFA2D730A03.md) - 2022-04-30 to 2022-07-31 | cash_and_equivalents | 638,190,000 United States dollar | superseded | [clm_F8AA1E398BB1](/claim/clm_F8AA1E398BB1.md) - 2022-05-31 to 2022-08-31 | shares_outstanding | 199,944,000 shares | superseded | [clm_22DFAA28DE83](/claim/clm_22DFAA28DE83.md) - 2022-07-31 to 2022-10-31 | total_equity | 407,131,000 United States dollar | superseded | [clm_2766B78C9882](/claim/clm_2766B78C9882.md) - 2022-07-31 to 2022-10-31 | cash_and_equivalents | 637,186,000 United States dollar | superseded | [clm_5802FAFABE4D](/claim/clm_5802FAFABE4D.md) - 2022-07-31 to 2022-10-31 | quarterly_research_and_development | 126,532,000 United States dollar | superseded | [clm_AA46D86EE949](/claim/clm_AA46D86EE949.md) - 2022-07-31 to 2022-10-31 | total_assets | 2,667,346,000 United States dollar | superseded | [clm_D4F6C7DF58F4](/claim/clm_D4F6C7DF58F4.md) - 2022-07-31 to 2022-10-31 | quarterly_operating_income | -41,090,000 United States dollar | superseded | [clm_D7E9F8270F23](/claim/clm_D7E9F8270F23.md) - 2022-07-31 to 2022-10-31 | quarterly_revenue | 622,184,000 United States dollar | superseded | [clm_E67F0A3F9915](/claim/clm_E67F0A3F9915.md) - 2022-07-31 to 2022-10-31 | quarterly_net_income | -45,078,000 United States dollar | superseded | [clm_FC08C0F0E831](/claim/clm_FC08C0F0E831.md) - 2022-08-31 to 2022-11-30 | shares_outstanding | 200,779,249 shares | superseded | [clm_2CEA4E957E6E](/claim/clm_2CEA4E957E6E.md) - 2022-10-31 to 2023-04-30 | quarterly_operating_income | -27,431,000 United States dollar | superseded | [clm_07CBF86E52C1](/claim/clm_07CBF86E52C1.md) - 2022-10-31 to 2023-01-31 | cash_and_equivalents | 632,620,000 United States dollar | superseded | [clm_4376AEA030A5](/claim/clm_4376AEA030A5.md) - 2022-10-31 to 2023-04-30 | quarterly_net_income | -29,866,000 United States dollar | superseded | [clm_6643B36D2B57](/claim/clm_6643B36D2B57.md) - 2022-10-31 to 2023-01-31 | total_assets | 2,731,584,000 United States dollar | superseded | [clm_8EC0038CC7A1](/claim/clm_8EC0038CC7A1.md) - 2022-10-31 to 2023-01-31 | total_equity | 468,506,000 United States dollar | superseded | [clm_A81D551F1ABF](/claim/clm_A81D551F1ABF.md) - 2022-10-31 to 2023-04-30 | quarterly_revenue | 645,463,000 United States dollar | superseded | [clm_C4CDF462F8D1](/claim/clm_C4CDF462F8D1.md) - 2022-10-31 to 2023-04-30 | quarterly_research_and_development | 115,934,000 United States dollar | superseded | [clm_EC4F902AE860](/claim/clm_EC4F902AE860.md) - 2022-11-30 to 2023-02-28 | shares_outstanding | 201,074,148 shares | superseded | [clm_4DE0F289DAAB](/claim/clm_4DE0F289DAAB.md) ## 2023 - 2023-01-31 to 2024-01-31 | research_and_development | 480,584,000 United States dollar | superseded | [clm_5A88DEAD7301](/claim/clm_5A88DEAD7301.md) - 2023-01-31 to 2024-01-31 | net_income | -97,454,000 United States dollar | superseded | [clm_68BC358AFDD4](/claim/clm_68BC358AFDD4.md) - 2023-01-31 to 2024-01-31 | operating_income | -88,031,000 United States dollar | superseded | [clm_6FE9E62AF6C5](/claim/clm_6FE9E62AF6C5.md) - 2023-01-31 to 2023-04-30 | total_equity | 617,287,000 United States dollar | superseded | [clm_941824DAE52F](/claim/clm_941824DAE52F.md) - 2023-01-31 to 2023-04-30 | total_assets | 3,012,720,000 United States dollar | superseded | [clm_A9B12F83E62D](/claim/clm_A9B12F83E62D.md) - 2023-01-31 to 2023-04-30 | cash_and_equivalents | 721,895,000 United States dollar | superseded | [clm_D5951F984898](/claim/clm_D5951F984898.md) - 2023-01-31 to 2024-01-31 | revenue | 2,515,915,000 United States dollar | superseded | [clm_E2FCF0B2C080](/claim/clm_E2FCF0B2C080.md) - 2023-02-22 | president | Robert Chatwani | valid | [clm_6B2E02777146](/claim/clm_6B2E02777146.md) - 2023-02-28 to 2023-05-31 | shares_outstanding | 201,904,828 shares | superseded | [clm_C47C16D0BE00](/claim/clm_C47C16D0BE00.md) - 2023-04-30 to 2023-07-31 | total_assets | 3,129,899,000 United States dollar | superseded | [clm_72BE121B7EF1](/claim/clm_72BE121B7EF1.md) - 2023-04-30 to 2023-07-31 | total_equity | 749,492,000 United States dollar | superseded | [clm_88A60E8E2D99](/claim/clm_88A60E8E2D99.md) - 2023-04-30 to 2023-07-31 | cash_and_equivalents | 940,494,000 United States dollar | superseded | [clm_AF4BC84C19F9](/claim/clm_AF4BC84C19F9.md) - 2023-04-30 to 2023-07-31 | quarterly_revenue | 661,388,000 United States dollar | superseded | [clm_BB80A6E75FC0](/claim/clm_BB80A6E75FC0.md) - 2023-04-30 to 2023-07-31 | quarterly_research_and_development | 115,364,000 United States dollar | superseded | [clm_ED57D6778BF8](/claim/clm_ED57D6778BF8.md) - 2023-04-30 to 2023-07-31 | quarterly_operating_income | -4,651,000 United States dollar | superseded | [clm_F0D88ACDA90E](/claim/clm_F0D88ACDA90E.md) - 2023-04-30 to 2023-07-31 | quarterly_net_income | 539,000 United States dollar | superseded | [clm_F2E24E5B4799](/claim/clm_F2E24E5B4799.md) - 2023-05-31 to 2023-08-31 | shares_outstanding | 202,371,035 shares | superseded | [clm_AD6EB175165E](/claim/clm_AD6EB175165E.md) - 2023-06-04 | board_member | Anna Marrs | valid | [clm_5BF660FFB4E1](/claim/clm_5BF660FFB4E1.md) - 2023-07-31 to 2023-10-31 | quarterly_revenue | 687,687,000 United States dollar | superseded | [clm_16E7463A4B30](/claim/clm_16E7463A4B30.md) - 2023-07-31 to 2023-10-31 | quarterly_net_income | 7,395,000 United States dollar | superseded | [clm_41B49E2ED04E](/claim/clm_41B49E2ED04E.md) - 2023-07-31 to 2023-10-31 | cash_and_equivalents | 1,017,778,000 United States dollar | superseded | [clm_7C44B9AE5642](/claim/clm_7C44B9AE5642.md) - 2023-07-31 to 2023-10-31 | quarterly_operating_income | 6,612,000 United States dollar | superseded | [clm_7FAB7617930D](/claim/clm_7FAB7617930D.md) - 2023-07-31 to 2023-10-31 | total_assets | 3,267,405,000 United States dollar | superseded | [clm_C0E5C650BA0B](/claim/clm_C0E5C650BA0B.md) - 2023-07-31 to 2023-10-31 | total_equity | 847,759,000 United States dollar | superseded | [clm_ED233C90BFAA](/claim/clm_ED233C90BFAA.md) - 2023-07-31 to 2023-10-31 | quarterly_research_and_development | 135,960,000 United States dollar | superseded | [clm_FE535929FFB2](/claim/clm_FE535929FFB2.md) - 2023-08-31 to 2023-11-30 | shares_outstanding | 203,205,081 shares | superseded | [clm_225B5BE54E57](/claim/clm_225B5BE54E57.md) - 2023-10-31 to 2024-04-30 | quarterly_revenue | 700,421,000 United States dollar | superseded | [clm_0A70F3E8A8B4](/claim/clm_0A70F3E8A8B4.md) - 2023-10-31 to 2024-01-31 | total_assets | 3,337,627,000 United States dollar | superseded | [clm_1584C331256C](/claim/clm_1584C331256C.md) - 2023-10-31 to 2024-04-30 | quarterly_net_income | 38,805,000 United States dollar | superseded | [clm_3DA70A98AE9C](/claim/clm_3DA70A98AE9C.md) - 2023-10-31 to 2024-01-31 | total_equity | 965,033,000 United States dollar | superseded | [clm_A3097736C21A](/claim/clm_A3097736C21A.md) - 2023-10-31 to 2024-01-31 | cash_and_equivalents | 1,188,578,000 United States dollar | superseded | [clm_AF2402F9A6D1](/claim/clm_AF2402F9A6D1.md) - 2023-10-31 to 2024-04-30 | quarterly_operating_income | 19,738,000 United States dollar | superseded | [clm_BA60008A08E1](/claim/clm_BA60008A08E1.md) - 2023-10-31 to 2024-04-30 | quarterly_research_and_development | 136,640,000 United States dollar | superseded | [clm_DE498486DE19](/claim/clm_DE498486DE19.md) - 2023-11-30 to 2024-02-29 | shares_outstanding | 203,933,894 shares | superseded | [clm_F222BEFE4B7F](/claim/clm_F222BEFE4B7F.md) ## 2024 - 2024-01-31 to 2024-04-30 | cash_and_equivalents | 797,060,000 United States dollar | superseded | [clm_0C22BC33AC76](/claim/clm_0C22BC33AC76.md) - 2024-01-31 to 2025-01-31 | research_and_development | 539,488,000 United States dollar | superseded | [clm_407397C9EDA5](/claim/clm_407397C9EDA5.md) - 2024-01-31 to 2025-01-31 | operating_income | 31,634,000 United States dollar | superseded | [clm_4ADD6B067B4F](/claim/clm_4ADD6B067B4F.md) - 2024-01-31 to 2025-01-31 | revenue | 2,761,882,000 United States dollar | superseded | [clm_72FF8E98DA44](/claim/clm_72FF8E98DA44.md) - 2024-01-31 to 2025-01-31 | net_income | 73,980,000 United States dollar | superseded | [clm_7A304C9814E4](/claim/clm_7A304C9814E4.md) - 2024-01-31 to 2024-04-30 | total_equity | 1,129,739,000 United States dollar | superseded | [clm_BE3C88E7CB68](/claim/clm_BE3C88E7CB68.md) - 2024-01-31 to 2024-04-30 | total_assets | 2,971,290,000 United States dollar | superseded | [clm_D84B094D290E](/claim/clm_D84B094D290E.md) - 2024-02-29 to 2024-05-31 | shares_outstanding | 205,415,129 shares | superseded | [clm_9A4B276142B0](/claim/clm_9A4B276142B0.md) - 2024-04-30 to 2024-07-31 | total_equity | 1,137,000,000 United States dollar | superseded | [clm_2A0B303D3BE3](/claim/clm_2A0B303D3BE3.md) - 2024-04-30 to 2024-07-31 | quarterly_revenue | 709,640,000 United States dollar | superseded | [clm_523AFD595D8D](/claim/clm_523AFD595D8D.md) - 2024-04-30 to 2024-07-31 | quarterly_net_income | 33,760,000 United States dollar | superseded | [clm_6C912B5070A4](/claim/clm_6C912B5070A4.md) - 2024-04-30 to 2024-07-31 | quarterly_operating_income | 22,628,000 United States dollar | superseded | [clm_7B951599FB97](/claim/clm_7B951599FB97.md) - 2024-04-30 to 2024-07-31 | quarterly_research_and_development | 134,320,000 United States dollar | superseded | [clm_7CD8B5AA2AC0](/claim/clm_7CD8B5AA2AC0.md) - 2024-04-30 to 2024-07-31 | cash_and_equivalents | 817,388,000 United States dollar | superseded | [clm_A9F8262639F3](/claim/clm_A9F8262639F3.md) - 2024-04-30 to 2024-07-31 | total_assets | 2,926,689,000 United States dollar | superseded | [clm_AA2DA954D933](/claim/clm_AA2DA954D933.md) - 2024-05-31 to 2024-08-30 | shares_outstanding | 204,716,354 shares | superseded | [clm_BC7AC15363D5](/claim/clm_BC7AC15363D5.md) - 2024-07-31 to 2024-10-31 | total_assets | 3,753,941,000 United States dollar | superseded | [clm_1931095B5CD5](/claim/clm_1931095B5CD5.md) - 2024-07-31 to 2024-10-31 | quarterly_research_and_development | 147,571,000 United States dollar | superseded | [clm_3FF101378767](/claim/clm_3FF101378767.md) - 2024-07-31 to 2024-10-31 | quarterly_operating_income | 57,801,000 United States dollar | superseded | [clm_60CD056E124C](/claim/clm_60CD056E124C.md) - 2024-07-31 to 2024-10-31 | quarterly_net_income | 888,211,000 United States dollar | superseded | [clm_6A40F3FF52D4](/claim/clm_6A40F3FF52D4.md) - 2024-07-31 to 2024-10-31 | total_equity | 1,961,406,000 United States dollar | superseded | [clm_F1927DB87F51](/claim/clm_F1927DB87F51.md) - 2024-07-31 to 2024-10-31 | quarterly_revenue | 736,027,000 United States dollar | superseded | [clm_F31BD71DE407](/claim/clm_F31BD71DE407.md) - 2024-07-31 to 2024-10-31 | cash_and_equivalents | 619,064,000 United States dollar | superseded | [clm_FC9B9C69A8AE](/claim/clm_FC9B9C69A8AE.md) - 2024-08-05 | president | Paula Hansen | valid | [clm_C0E06679790C](/claim/clm_C0E06679790C.md) - 2024-08-30 to 2024-11-29 | shares_outstanding | 202,972,713 shares | superseded | [clm_A7821C63A943](/claim/clm_A7821C63A943.md) - 2024-10-31 to 2025-01-31 | cash_and_equivalents | 610,870,000 United States dollar | superseded | [clm_0F131700E612](/claim/clm_0F131700E612.md) - 2024-10-31 to 2025-04-30 | quarterly_revenue | 754,820,000 United States dollar | superseded | [clm_8D16E712FBCC](/claim/clm_8D16E712FBCC.md) - 2024-10-31 to 2025-01-31 | total_assets | 3,770,208,000 United States dollar | superseded | [clm_9A1A9C3E5DAA](/claim/clm_9A1A9C3E5DAA.md) - 2024-10-31 to 2025-04-30 | quarterly_research_and_development | 151,101,000 United States dollar | superseded | [clm_B14C0C8DEC9B](/claim/clm_B14C0C8DEC9B.md) - 2024-10-31 to 2025-04-30 | quarterly_operating_income | 59,030,000 United States dollar | superseded | [clm_B797AEFB7DCD](/claim/clm_B797AEFB7DCD.md) - 2024-10-31 to 2025-04-30 | quarterly_net_income | 62,423,000 United States dollar | superseded | [clm_BBBADF46EB83](/claim/clm_BBBADF46EB83.md) - 2024-10-31 to 2025-01-31 | total_equity | 1,989,377,000 United States dollar | superseded | [clm_D62A0F872E3C](/claim/clm_D62A0F872E3C.md) - 2024-11-29 to 2025-02-28 | shares_outstanding | 202,023,141 shares | superseded | [clm_8AFF402E0553](/claim/clm_8AFF402E0553.md) ## 2025 - 2025-01-31 to 2026-01-31 | research_and_development | 588,455,000 United States dollar | superseded | [clm_23AA666D376E](/claim/clm_23AA666D376E.md) - 2025-01-31 to 2025-04-30 | total_equity | 2,002,692,000 United States dollar | superseded | [clm_435A2237CD73](/claim/clm_435A2237CD73.md) - 2025-01-31 to 2026-01-31 | revenue | 2,976,739,000 United States dollar | superseded | [clm_5FFE2F28CCDC](/claim/clm_5FFE2F28CCDC.md) - 2025-01-31 to 2026-01-31 | net_income | 1,067,885,000 United States dollar | superseded | [clm_663C6FB31595](/claim/clm_663C6FB31595.md) - 2025-01-31 to 2025-04-30 | total_assets | 4,012,705,000 United States dollar | superseded | [clm_93943D2DD64E](/claim/clm_93943D2DD64E.md) - 2025-01-31 to 2025-04-30 | cash_and_equivalents | 648,623,000 United States dollar | superseded | [clm_98F88A43D36D](/claim/clm_98F88A43D36D.md) - 2025-01-31 to 2026-01-31 | operating_income | 199,928,000 United States dollar | superseded | [clm_D1AF150A404D](/claim/clm_D1AF150A404D.md) - 2025-02-28 to 2025-05-30 | shares_outstanding | 202,489,720 shares | superseded | [clm_3108C895F5CE](/claim/clm_3108C895F5CE.md) - 2025-04-30 to 2025-07-31 | cash_and_equivalents | 657,399,000 United States dollar | superseded | [clm_16AB18C845B3](/claim/clm_16AB18C845B3.md) - 2025-04-30 to 2025-07-31 | quarterly_operating_income | 60,255,000 United States dollar | superseded | [clm_75143F4B5D35](/claim/clm_75143F4B5D35.md) - 2025-04-30 to 2025-07-31 | quarterly_net_income | 72,087,000 United States dollar | superseded | [clm_86F876FCEA3A](/claim/clm_86F876FCEA3A.md) - 2025-04-30 to 2025-07-31 | total_assets | 3,947,403,000 United States dollar | superseded | [clm_A8AF8E818FC6](/claim/clm_A8AF8E818FC6.md) - 2025-04-30 to 2025-07-31 | quarterly_revenue | 763,654,000 United States dollar | superseded | [clm_F43EF51515DE](/claim/clm_F43EF51515DE.md) - 2025-04-30 to 2025-07-31 | quarterly_research_and_development | 159,447,000 United States dollar | superseded | [clm_F67F4C278FAC](/claim/clm_F67F4C278FAC.md) - 2025-04-30 to 2025-07-31 | total_equity | 2,014,802,000 United States dollar | superseded | [clm_FEED977863A4](/claim/clm_FEED977863A4.md) - 2025-05-30 to 2025-08-29 | shares_outstanding | 202,062,772 shares | superseded | [clm_1E74D7384282](/claim/clm_1E74D7384282.md) - 2025-07-31 to 2025-10-31 | quarterly_operating_income | 65,227,000 United States dollar | superseded | [clm_1D0777B6E845](/claim/clm_1D0777B6E845.md) - 2025-07-31 to 2025-10-31 | quarterly_net_income | 62,970,000 United States dollar | superseded | [clm_577437B2DEC8](/claim/clm_577437B2DEC8.md) - 2025-07-31 to 2025-10-31 | quarterly_research_and_development | 169,630,000 United States dollar | superseded | [clm_6CCF3194D750](/claim/clm_6CCF3194D750.md) - 2025-07-31 to 2025-10-31 | total_equity | 1,987,975,000 United States dollar | superseded | [clm_83352E0A2192](/claim/clm_83352E0A2192.md) - 2025-07-31 to 2025-10-31 | quarterly_revenue | 800,636,000 United States dollar | superseded | [clm_951E59437A76](/claim/clm_951E59437A76.md) - 2025-07-31 to 2025-10-31 | cash_and_equivalents | 599,986,000 United States dollar | superseded | [clm_F630833400AF](/claim/clm_F630833400AF.md) - 2025-07-31 to 2025-10-31 | total_assets | 3,949,923,000 United States dollar | superseded | [clm_FFE0501E5396](/claim/clm_FFE0501E5396.md) - 2025-08-29 to 2025-11-30 | shares_outstanding | 201,104,117 shares | superseded | [clm_70AA9C296E68](/claim/clm_70AA9C296E68.md) - 2025-09-03 | board_member | Mike Rosenbaum | valid | [clm_19A4D9A646CA](/claim/clm_19A4D9A646CA.md) - 2025-10-31 to 2026-01-31 | total_assets | 3,982,039,000 United States dollar | superseded | [clm_69418220C405](/claim/clm_69418220C405.md) - 2025-10-31 to 2026-01-31 | cash_and_equivalents | 583,291,000 United States dollar | superseded | [clm_69687F7FEF18](/claim/clm_69687F7FEF18.md) - 2025-10-31 to 2026-04-30 | quarterly_revenue | 818,350,000 United States dollar | superseded | [clm_7EBBB4DAE457](/claim/clm_7EBBB4DAE457.md) - 2025-10-31 to 2026-04-30 | quarterly_operating_income | 85,355,000 United States dollar | superseded | [clm_A6AE32965D96](/claim/clm_A6AE32965D96.md) - 2025-10-31 to 2026-04-30 | quarterly_research_and_development | 167,626,000 United States dollar | superseded | [clm_BBB6F876D421](/claim/clm_BBB6F876D421.md) - 2025-10-31 to 2026-01-31 | total_equity | 1,981,521,000 United States dollar | superseded | [clm_CA1325D2C153](/claim/clm_CA1325D2C153.md) - 2025-10-31 to 2026-04-30 | quarterly_net_income | 83,725,000 United States dollar | superseded | [clm_D485611E1223](/claim/clm_D485611E1223.md) - 2025-11-30 to 2026-02-28 | shares_outstanding | 200,272,740 shares | superseded | [clm_217A75E51405](/claim/clm_217A75E51405.md) ## 2026 - 2026-01-31 | operating_income | 298,579,000 United States dollar | valid | [clm_24B824625716](/claim/clm_24B824625716.md) - 2026-01-31 | revenue | 3,219,500,000 United States dollar | valid | [clm_29CDF590BAD5](/claim/clm_29CDF590BAD5.md) - 2026-01-31 | net_income | 309,085,000 United States dollar | valid | [clm_30AB2D83FB0B](/claim/clm_30AB2D83FB0B.md) - 2026-01-31 | research_and_development | 664,985,000 United States dollar | valid | [clm_38DBD328227D](/claim/clm_38DBD328227D.md) - 2026-01-31 to 2026-04-30 | cash_and_equivalents | 602,442,000 United States dollar | superseded | [clm_8D506CFA8FB5](/claim/clm_8D506CFA8FB5.md) - 2026-01-31 to 2026-04-30 | total_assets | 4,229,550,000 United States dollar | superseded | [clm_9B6A5020BAAE](/claim/clm_9B6A5020BAAE.md) - 2026-01-31 to 2026-04-30 | total_equity | 1,917,820,000 United States dollar | superseded | [clm_A106BA37F17B](/claim/clm_A106BA37F17B.md) - 2026-02-28 to 2026-05-29 | shares_outstanding | 194,427,928 shares | superseded | [clm_D4DFB74A758C](/claim/clm_D4DFB74A758C.md) - 2026-03-05 | board_member | Brian Roberts | valid | [clm_B5BADA9F9A96](/claim/clm_B5BADA9F9A96.md) - 2026-04-30 to 2026-07-31 | total_equity | 1,819,748,000 United States dollar | superseded | [clm_0BAB23CA87C8](/claim/clm_0BAB23CA87C8.md) - 2026-04-30 to 2026-07-31 | quarterly_revenue | 830,235,000 United States dollar | superseded | [clm_21565D249F4C](/claim/clm_21565D249F4C.md) - 2026-04-30 to 2026-07-31 | total_assets | 3,984,005,000 United States dollar | superseded | [clm_40691C6364D3](/claim/clm_40691C6364D3.md) - 2026-04-30 to 2026-07-31 | quarterly_research_and_development | 159,586,000 United States dollar | superseded | [clm_985EC3D38185](/claim/clm_985EC3D38185.md) - 2026-04-30 to 2026-07-31 | quarterly_net_income | 78,197,000 United States dollar | superseded | [clm_A78E892E3D34](/claim/clm_A78E892E3D34.md) - 2026-04-30 to 2026-07-31 | cash_and_equivalents | 548,027,000 United States dollar | superseded | [clm_D9204CF5DB4A](/claim/clm_D9204CF5DB4A.md) - 2026-04-30 to 2026-07-31 | quarterly_operating_income | 111,309,000 United States dollar | superseded | [clm_FAC8268EDE29](/claim/clm_FAC8268EDE29.md) - 2026-05-02 | board_member | Rowan Trollope | valid | [clm_8ED4E319DA9B](/claim/clm_8ED4E319DA9B.md) - 2026-05-29 to 2026-08-31 | shares_outstanding | 190,944,608 shares | superseded | [clm_1583A063E9D8](/claim/clm_1583A063E9D8.md) - 2026-07-31 | total_assets | 3,960,790,000 United States dollar | valid | [clm_2D440EDB0673](/claim/clm_2D440EDB0673.md) - 2026-07-31 | quarterly_revenue | 875,746,000 United States dollar | valid | [clm_6F67F9829AB9](/claim/clm_6F67F9829AB9.md) - 2026-07-31 | quarterly_operating_income | 117,621,000 United States dollar | valid | [clm_9726E74680D3](/claim/clm_9726E74680D3.md) - 2026-07-31 | quarterly_research_and_development | 163,582,000 United States dollar | valid | [clm_A1598A80E32B](/claim/clm_A1598A80E32B.md) - 2026-07-31 | quarterly_net_income | 77,715,000 United States dollar | valid | [clm_A8F6A578CA64](/claim/clm_A8F6A578CA64.md) - 2026-07-31 | cash_and_equivalents | 528,161,000 United States dollar | valid | [clm_E818FAA2B60A](/claim/clm_E818FAA2B60A.md) - 2026-07-31 | total_equity | 1,718,520,000 United States dollar | valid | [clm_F377D2C0B227](/claim/clm_F377D2C0B227.md) - 2026-08-31 | shares_outstanding | 186,902,452 shares | valid | [clm_9E5DC983185C](/claim/clm_9E5DC983185C.md) --- AsOf is a temporal fact ledger: a structured, dated, sourced record of what is true and what changed, built for AI retrieval.